Guselkumab
Guselkumab
Guselkumab (pronounced goo-sel-koo-mab) is a human monoclonal antibody that is used for the treatment of moderate to severe plaque psoriasis. It is marketed under the brand name Tremfya.
Etymology
The name Guselkumab is derived from its structure and function. The suffix "-mab" is an acronym for Monoclonal Antibody, indicating that Guselkumab is a type of monoclonal antibody. The prefix "Gusel-" does not have a specific meaning and is used for naming purposes.
Mechanism of Action
Guselkumab works by binding to a specific protein called interleukin-23 (IL-23), which is involved in inflammatory and immune responses. By blocking the action of IL-23, Guselkumab helps to reduce the inflammation and other symptoms of psoriasis.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Interleukin-23 (IL-23): A type of protein in the immune system that plays a key role in inflammation and immune responses.
- Psoriasis: A chronic skin condition that causes cells to build up rapidly on the surface of the skin, forming scales and red patches that are sometimes painful or itchy.
- Plaque Psoriasis: The most common form of psoriasis, characterized by raised, inflamed, red lesions covered by a silvery white scale.
See Also
External links
- Medical encyclopedia article on Guselkumab
- Wikipedia's article - Guselkumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski